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Temporoparietal and posterior cingulate metabolism deficits characterize patients with Alzheimer’s disease (AD). A H2
15O resting PET
scan covariance pattern, derived by using multivariate techniques, was previously shown to discriminate 17 mild AD patients from 16
healthy controls. This AD covariance pattern revealed hypoperfusion in bilateral inferior parietal lobule and cingulate; and left middle
frontal, inferior frontal, precentral, and supramarginal gyri. The AD pattern also revealed hyperperfusion in bilateral insula, lingual gyri, and
cuneus; left fusiform and superior occipital gyri; and right parahippocampal gyrus and pulvinar. In an independent sample of 23 outpatients
with mild cognitive impairment (MCI) followed at 6-month intervals, the AD pattern score was evaluated as a predictor of cognitive
decline. In this MCI sample, an H2
15O resting PET scan was carried out at baseline. Mean duration of follow-up was 48.8 (SD 15.5)
months, during which time six of 23 MCI patients converted to AD. In generalized estimating equations (GEE) analyses, controlling for
age, sex, education, and baseline neuropsychological scores, increased AD pattern score was associated with greater decline in each
neuropsychological test score over time (Mini Mental State Exam, Selective Reminding Test delayed recall, Animal Naming, WAIS-R digit
symbol; Pso0.01–0.001). In summary, a resting PET covariance pattern previously reported to discriminate AD patients from control
subjects was applied prospectively to an independent sample of MCI patients and found to predict cognitive decline. Independent
replication in larger samples is needed before clinical application can be considered.
Neuropsychopharmacology (2006) 31, 1327–1334. doi:10.1038/sj.npp.1300942; published online 9 November 2005


























































Regional cerebral blood flow (rCBF) and metabolism
(rCMRglc) deficits, primarily in the temporoparietal and
posterior cingulate regions, are early features of Alzheimer’s
disease (AD). Decreased rCBF and rCMRglc may represent
metabolic insufficiency prior to neuronal loss, may be
secondary to local neuronal loss, or may reflect amyloid-
related vascular pathology in the walls of blood vessels
(Gsell et al, 2000; Cummings, 2004). Another contributing
factor may be the loss of cholinergic projections from the
basal forebrain to the hippocampus and neocortex.
Temporoparietal metabolism deficits characteristically
distinguish AD from controls, with high sensitivity (around
90% across studies) but only moderate specificity (Hoffman
et al, 2000; Silverman et al, 2001; Herholz et al, 2002). Most
of these studies included patients with moderate to severe
AD, and predictive accuracy may not be as high in mild AD
(Ishii et al, 1997; Herholz et al, 1999; De Santi et al, 2001).
Nonetheless, expert clinical reading of PET may improve
diagnostic accuracy for AD with reductions in false
negatives and false positives (Silverman et al, 2001, 2002).
In addition to temporoparietal deficits, posterior cingulate
hypometabolism, which may reflect compromised projec-
tions from medial temporal regions, may characterize AD
(Aupee et al, 2001; Millien et al, 2002).
The utility of these rCBF and rCMGRglc deficits in
predicting cognitive decline in cognitively impaired, non-
demented patients is not established (Minoshima et al,
1997; Arnaiz et al, 2001; Huang et al, 2002). Cognitive
processes generally reflect activity across brain networks
rather than discrete regions in isolation, and this functional
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connectivity can be evaluated by multivariate methods
(Alexander and Moeller, 1994; Friston, 1994). Using resting
H2
15O PET, we reported that a multivariate technique (Scaled
Subprofile Modeling or SSM) that examines covariance
patterns to identify alterations in network expression
successfully discriminated mild AD patients from healthy
control subjects (p¼ 0.03; sensitivity 76%, specificity 81% at
the optimal cut-point for the covariance pattern), whereas
SPM and ROI analyses did not show significant differences
(Scarmeas et al, 2004). The previously identified covariance
pattern showed negative loadings (hypoperfusion) in
bilateral inferior parietal lobule and cingulate; and left
middle frontal, inferior frontal, precentral and supramar-
ginal gyri. Positive loadings (hyperperfusion) were seen in
bilateral insula, lingual gyri, and cuneus; left fusiform and
superior occipital gyri; and right parahippocampal gyrus
and pulvinar. The mean pattern expression was significantly
greater in AD patients compared to controls, even after
controlling for age.
In the same report, we described resting H2
15O PET results
in outpatients with mild cognitive impairment (MCI), who
presented with memory complaints and demonstrated
cognitive deficits on neuropsychological testing. In the
MCI sample examined cross-sectionally, the identified
covariance pattern (AD pattern) differentiated patients with
baseline Clinical Dementia Rating (CDR) 0 from patients
with baseline CDR 0.5 (questionable dementia), and it
inversely correlated with neuropsychological measures
(Scarmeas et al, 2004). In this longitudinal study, we
hypothesized that forward application of the previously
identified AD pattern would predict cognitive decline over
time in the MCI sample.
MATERIALS AND METHODS
Subjects
Patients who presented with memory complaints to a
Memory Disorders Center participated in a longitudinal
study of putative early diagnostic markers of AD. The
research protocol was approved by the New York State
Psychiatric Institute and Columbia Presbyterian Medical
Center IRBs, and written informed consent was obtained.
For patients, inclusion criteria were age X40 years,
intellectual impairmentX6 months andp10 years, and the
diagnosis of ‘not demented’ (CDR¼ 0) or ‘questionably
demented’ (CDR¼ 0.5). Patients had a minimum modified
mMMSE score X40 out of 57 (Folstein MMSE X22).
Neuropsychological testing screening guidelines were recall
p2 out of three objects at 5 min on the Mini Mental State
Exam (MMSE), or a delayed recall score 41 SD below
norms on the Selective Reminding Test (SRT), or a
Wechsler Adult Intelligence Scale-Revised (WAIS-R) per-
formance IQ scoreX10 points below the WAIS-R verbal IQ
score (Devanand et al, 2000; Tabert et al, 2002). Patients
without any of these deficits were eligible if they met all the
following criteria: subjective complaint of memory decline,
informant’s confirmation of decline, and a positive score on
at least one of the first eight items of the modified Blessed
Functional Activity Scale (Devanand et al, 2005).
Exclusion criteria were a diagnosis of dementia, schizo-
phrenia, schizoaffective disorder, or primary major affective
disorder, electroconvulsive therapy within the past 6
months, current or recent (past 6 months) history of
alcohol or substance dependence (DSM-IV criteria), clinical
or historical evidence of stroke, cortical stroke or an infarct
X2 cm in diameter on any MRI slice, cognitive impairment
rated as entirely caused by concomitant medications, and
major neurological illness.
Patients who met these inclusion/exclusion criteria were
defined as having MCI and were followed at 6-month
intervals (Devanand et al, 2005). The physician’s assess-
ment, Folstein MMSE, and SRT were completed at each 6-
month interval, with the entire neuropsychological test
battery administered at annual visits.
Procedures
The study physician (neurologist or psychiatrist) completed
a medical history and conducted a general physical,
neurological, and psychiatric examination. Laboratory tests
included complete blood count with differential, serum
electrolytes, liver and renal function tests, thyroid function
tests, VDRL, serum B12 and folate levels, and brain MRI
scan. A trained neuropsychology technician administered
the following tests: WAIS-R, Wechsler Memory Scale
(WMS), SRT (12-item), Rosen Drawing Test, Controlled
Oral Word Association, category naming from the Boston
Diagnostic Aphasia Evaluation, Boston Naming Test,
Benton Visual Retention Test, and Target Finding (shape
and letter cancellation tasks). The analyses of neuropsycho-
logical variables were restricted a priori to the Folstein
MMSE and single measures of verbal memory (SRT delayed
recall), verbal fluency (Animal Naming), and attention/
executive function (WAIS-R digit symbol), which are well-
established predictors of MCI conversion to AD (Jacobs
et al, 1995; Devanand et al, 2005).
The neuropsychological scores were evaluated by an
experienced neuropsychologist (YS), and two expert clinical
raters (DPD and YS) used these results, clinical and
laboratory test results, and MRI clinical reads to make a
consensus research diagnosis at all visits (Devanand et al,
2000, 2005; Tabert et al, 2002). The diagnosis of dementia
was based on DSM-IV criteria, and the diagnosis of possible
or probable AD was based on NINCDS-ADRDA criteria
(McKhann et al, 1984). PET results did not play any role in
the diagnostic process. Apolipoprotein E genotype was
assessed in all subjects (Hixson and Powers, 1991), and
patients were characterized as e4 carriers (e3/e4 or e2/e4 or
e4/e4) or e4 noncarriers.
PET Scan Acquisition and Processing
A Siemens EXACT 47 PET camera (Knoxville, TN, USA) was
used to acquire resting H2
15O PET scans. A bolus of 30 mCi
H2
15O was injected intravenously. Scan acquisition was
triggered by the detection of a threshold level of true counts
from the camera. Two 30-s scan frames were acquired in 2-
D mode, which were subsequently averaged to yield a single
image per subject. After measured attenuation correction
(15-min transmission scan) and reconstruction by filtered
back-projection, image resolution was 4.6 mm full-width at
half-maximum (FWHM). Arterial blood sampling was not
conducted, thus only nonquantitative count images (and
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not absolute rCBF measures) were obtained. Each subject’s
image was spatially transformed to the PET Montreal
Neurological Institute brain space template included with
the SPM99 program (Wellcome Department of Neurology).
The spatially transformed images were smoothed with an
isotropic, Gaussian kernel (FWHM¼ 12 mm).
Covariance Analysis
The spatial covariance analytic method, SSM, is a form of
principal component analysis that captures regionally
correlated local percent changes from the mean voxel
activity of a reference subject group, without contamination
by subject differences in global blood flow (Alexander and
Moeller, 1994; Moeller et al, 1987). This method has been
used to distinguish the blood flow pattern (and metabolism
pattern using FDG PET) in patients with specific neurolo-
gical and psychiatric disorders from the pattern observed in
normal control subjects (Eidelberg et al, 1998; Stern et al,
2000; Su et al, 2001).
We reported on the derivation of a covariance analysis-
based blood flow pattern that distinguished AD patients
from healthy controls, as described elsewhere in detail
(Scarmeas et al, 2004). In this longitudinal study, the
previously derived AD covariance pattern was prospectively
applied to the PET perfusion data in the independent
sample of 23 MCI patients. The operation of forward
application was represented mathematically by a ‘dot’
product computation: every voxel value in a subject scan
was multiplied by the corresponding voxel weight in the AD
pattern, with a subsequent summation over the whole brain
volume to derive the subject scaling factor, or SSF, for the
subject. This SSF factor quantifies the degree of AD pattern
expression in each subject’s PET scan; we refer to the AD
pattern score as the SSF. The SSF was tested as a predictor
of cognitive decline in the MCI sample.
ROI Analyses
T1-weighted anatomical MRI scans from eight elderly
healthy control subjects (mean age 67.3, SD 4.2 years, 75%
male, no neurological or psychiatric disorder, no cognitive
impairment) were acquired axially on a 1.5-T GE scanner
(1.5-mm slice thickness, 0.86-mm in-plane resolution,
TE¼ 5 ms, TR¼ 34 ms). The MRIs were reoriented coron-
ally, AC-PC aligned and then segmented and parcellated
into 130 regions (96 of them cortical gray matter) using the
Cardviews software program (Goldstein et al, 1999). A
single rater, who had been formally trained by the Card-
views group, labeled each region in a semiautomated
manner using a combination of hand-drawing with a cursor
and local thresholding with a histogram. The labeled brains
were spatially normalized into MNI space (FLIRT from FSL,
developed by FMRIB, Oxford, http://www.fmrib.ox.ac.uk).
A probabilistic atlas in this standard space was constructed
by allowing each atlas brain to contribute equally to the
region identity for each voxel. For example, at Talairach [4,
34,38], 6/8 report ‘Right Posterior Cingulate Gyrus’ and 2/8
report ‘Right White Matter’, so the probabilities assigned
to those two regions at that voxel are 0.75 and 0.25,
respectively. The PET images were registered to this space
and the regional CBF was determined by taking a weighted
average of the CBF voxel values over each probabilistically
defined region. ROI analyses were conducted for three
regions (sum of right and left) selected a priori based on the
literature: hippocampus, parahippocampus, and posterior
cingulate (Ishii et al, 1997; Herholz et al, 1999, 2002; De
Santi et al, 2001), followed by exploratory ROI analyses for
all 130 regions.
Statistics
Two-tailed t-test and w2 test (or Fisher’s exact test) were used
to compare the features of patients and controls. We used
generalized estimating equations (GEE) to test whether the
AD pattern score (SSF) was associated with differential rates
of cognitive decline (Liang and Zeger, 1986). GEE takes into
account the multiple visits per subject and the fact that the
characteristics of the same subject over time are likely to be
correlated. The repeated measures for each subject are
treated as a cluster. The GEE model included each of four
neuropsychological scores as the dependent variable and, as
predictors, the AD pattern score (SSF), time (years from
baseline assessment), and an SSF time interaction. GEE
models were additionally adjusted for baseline age, sex,
education, and baseline neuropsychological scores.
Conversion to AD was defined as meeting clinical
diagnostic criteria for probable AD at two consecutive
assessments (6-month intervals). Only six patients con-
verted to AD, so the analyses for prediction of conversion to
AD were considered exploratory. Since follow-up duration
varied across subjects, Cox proportional hazards models
were used to examine the effect of the previously identified
AD pattern score (SSF) on the development of AD,
controlling for sex, baseline age, education and baseline
MMSE scores. The time variable was the initial visit to the
first follow-up time-point at which AD was diagnosed. An
ROC curve was plotted to determine the optimal AD pattern
score (SSF) for prediction of the follow-up diagnosis of AD.
Similar GEE and Cox analyses were conducted for the ROIs,
focusing on the three ROI measures selected a priori.
RESULTS
Sample Characteristics
The demographic and clinical features of the sample are
described in Table 1. Mean duration of follow-up was 48.8
(SD 15.5) months with an average of 8 (SD 2.3) assessments
per subject. Converters to AD reached their conversion
time-point an average of 42 (SD 15.2) months after the
initial evaluation. Nonconverters (n¼ 17) were followed for
an average of 51.2 (SD 15.3) months. Converters to AD
during follow-up (n¼ 6) were older than the 17 non-
converters, and had lower baseline MMSE, SRT delayed
recall, and WAIS-R digit symbol scores (Table 1).
AD Covariance Pattern (SSF)
The AD pattern score (SSF) showed a trend-level correlation
with age (r¼ 0.37, p¼ 0.08) but was not associated with sex
or education.
In the MCI sample (n¼ 23), GEE analyses were conducted
on the time trend in MMSE, SRT delayed recall, Animal
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Naming and WAIS-R digit symbol scores, respectively. For
the linear time trend in MMSE, after controlling for age, sex,
education, and baseline MMSE, there was a significant time
effect (po0.02), and a significant SSF (AD pattern score) by
time interaction (po0.002; Figure 1). More robust results
were obtained for the other three neuropsychological
measures in similar GEE analyses with the same covariates.
For SRT delayed recall, there was a significant time effect
(po0.0001) and a significant SSF by time interaction
(po0.0001). For animal naming, there was a significant
time effect (po0.0001) and a significant SSF by time
interaction (po0.0001). For WAIS-R digit symbol, there
was a significant time effect (po0.001) and a significant SSF
by time interaction (po0.001).
In the MCI sample, the AD pattern score (SSF) tended to
be associated with the follow-up diagnosis of AD (p¼ 0.1).
Figure 2 illustrates the scatter-plot of the SSF values in the
MCI converters and nonconverters to AD, and in the
previously reported AD (n¼ 17) and healthy control
(n¼ 16) groups (Scarmeas et al, 2004). Based on an ROC
curve, the optimal SSF value was 23, which was nearly
identical to the sample median (22.8) and led to a sensitivity
of 83.3% and specificity of 58.8% for prediction of the
follow-up diagnosis of AD. The area under the ROC curve
(AUC) was 0.735. Since only six patients converted to AD,
Cox proportional hazards model analyses were exploratory.
In these analyses, the SSF was not a significant predictor
of conversion to AD (po0.17), and neither was the SSF
dichotomized around the optimal value based on the
ROC curve (SSF¼ 23; risk ratio¼ 5.3, 95% CI 0.6–45.8,
p¼ 0.13).
ROI Analyses
ROI analyses were conducted for three a priori regions (sum
of right and left): hippocampus, parahippocampus, and
posterior cingulate. In univariate analyses, among these
three ROIs, only flow reduction in the posterior cingulate







Sex, %F 26 74 0.06
Age in years, mean7SD 75.074.9 65.879.7 0.04
Education in years, mean7SD 17.871.6 16.472.2 0.16
Ethnic group
Whites (%) 100 88.2 0.6
Hispanics (%) 0 5.9 F
Blacks (%) 0 0 F
Other (%) 0 5.9 F
MMSE, mean7SD 27.270.36 29.070.94 0.001
SRT delayed recall, mean7SD 2.771.9 6.973.3 0.01
Animal naming, mean7SD 19.175.9 20.375.2 0.67
WAIS-R digit symbol, mean7SD 38.076.9 49.8712.2 0.04
Apolipoprotein E e4 carrier 66.7% 23.5% 0.09
Subject Scaling Factor (SSF) 26.475.7 21.975.7 0.12
aA test of significance (p¼ probability) for w2 or Fisher’s exact test (categorical
variables) or two-tailed t-test (continuous variables), conducted as appropriate.
MMSE: 30-item Mini-Mental State Exam; SRT: Selective Reminding Test of
Buschke and Fuld; WAIS-R: Wechsler Adult Intelligence Scale-Revised; SSF:
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3 4 5
Figure 1 Summary of generalized estimating equations (GEE) analyses
on the effect of the baseline covariance pattern (SSF, dichotomized around
median score 23) on change in Mini Mental State Exam (MMSE) over time,
controlling for age, sex, education and baseline MMSE. For patients with
high SSF expression, open squares represent the mean MMSE values at
each visit used in the GEE analyses, and for patients with low SSF
expression, solid circles represent the mean MMSE values at each visit. The
corresponding regression lines (broken line for high SSF and solid line for
























Figure 2 AD pattern expression values (SSF) in 16 healthy control
subjects, 17 MCI nonconverters to AD, six MCI converters to AD, and 17
AD patients.
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predicted conversion to AD (po0.05, two-tailed t-test,
corrected for three comparisons). In a Cox proportional
hazards model, the posterior cingulate was not a significant
predictor of conversion to AD (po0.15), and it remained
nonsignificant (po0.3) after controlling for age, sex,
education, and baseline MMSE. In similar Cox analyses,
neither the hippocampus nor the parahippocampus ROI
was significant.
Next, we computed the average blood flow in 130 gray-
and white-matter ROIs and proportionally scaled them by
the whole-brain flow value. In exploratory univariate
analyses (two-tailed t-tests), only two brain regions showed
lower values for converters compared to nonconverters
(right and left posterior cingulate, po0.05), which became
nonsignificant after correcting for multiple comparisons.
In GEE analyses, controlling for age, sex, education, and
corresponding baseline neuropsychological score, there was
no significant posterior cingulate (sum of right and left) by
time interaction on the time trend in MMSE or SRT delayed
recall or WAIS-R digit symbol scores. In comparable GEE
analyses, there was a significant posterior cingulate by time
interaction on the time trend in Animal Naming (po0.02).
In similar GEE analyses on the same neuropsychological
variables using the same covariates, there were no
significant hippocampus by time or parahippocampus by
time interactions.
Apolipoprotein E e4 Allele
Among the six converters to AD, four (66.7%) were e4
carriers (two heterozygous and two homozygous) compared
to four of 17 (23.5%) e4 carriers (all heterozygous) among
nonconverters to AD (Fisher’s exact test, po0.14). Three of
six (50%) e4 carriers with high SSF scores (423) converted
to AD, compared to two of 15 (11.8%) converters in the rest
of the sample (Fisher’s exact test, po0.09). In a Cox model,
patients who were e4 carriers with high AD pattern
expression (SSF423) tended to be more likely to convert
to AD than the rest of the sample (risk ratio 4.2, 95%
CI 0.9–21, po0.08), but this effect became nonsignificant
after controlling for age, sex, education and baseline
MMSE.
DISCUSSION
In our recent report, multivariate analysis was superior to
univariate methods in discriminating mild AD from
controls, and in the MCI sample, patients with CDR 0
differed in their AD pattern scores from patients with CDR
0.5 (Scarmeas et al, 2004). In this longitudinally studied
MCI sample, in GEE analyses for all four neuropsycholo-
gical measures, this AD pattern score was associated with
greater cognitive decline over time even after controlling for
age, sex, education, and baseline cognitive test performance.
This result indicates the unique strength of this study, in
that a covariance pattern that was empirically derived as
discriminating AD patients from control subjects was then
forward-applied to an independent sample of MCI patients
and found to have predictive utility for cognitive decline
during follow-up, even after controlling for relevant
demographic variables and baseline cognitive scores.
Other investigators have utilized multivariate analytic
techniques to distinguish AD from control subjects (Azari
et al, 1993; Grady et al, 2001) and to predict conversion to
AD (Johnson et al, 1998). In a Tc-HMPAO SPECT study, the
pattern derived from multivariate analysis showed 84.4%
accuracy in discriminating 27 questionable dementia
patients who did not progress from 18 questionable
dementia subjects who converted to AD during 2 years of
follow-up (Johnson et al, 1998). Less information is
available on the utility of PET abnormalities in predicting
cognitive decline in healthy control subjects. Using tradi-
tional analytic techniques, de Leon et al (2001) showed that
reduction in entorhinal glucose metabolism (FDG PET) was
associated with cognitive decline in a sample of 48 normal
elderly subjects followed for 3 years, with entorhinal
metabolism correctly classifying cognitive decline with
84% accuracy.
In exploratory Cox survival analyses, we found that the
AD pattern score was not a significant predictor of
conversion to AD. The risk ratio was fairly high (5.3
without controlling for other variables), but the variability
led to wide confidence intervals and reduction in signifi-
cance in this small sample. Two nonconverters expressed
the AD pattern to a marked degree: one of them has begun
to show cognitive decline after 4 years of follow-up and
another is cognitively stable. Both subjects are apoE e4
carriers, and high AD pattern scores in e4 carriers tended to
be associated with an increased risk of conversion to AD,
consistent with other reports that used different analytic
techniques (Small et al, 1995; Reiman et al, 1996). Other
PET reports in MCI (or similar) samples followed long-
itudinally have also involved small numbers of subjects, and
have generally utilized univariate techniques. In 20 MCI
patients followed for an average of 3 years, the strongest
predictors of AD were decreased rCMRglu from the left
temporoparietal area and impaired performance on block
design (Arnaiz et al, 2001). In other studies of small samples
of MCI patients followed for up to 2 years, lower
temporoparietal FDG uptake or posterior cingulate hypo-
metabolism characterized conversion to AD (Chetelat et al,
2003; Drzezga et al, 2003). In another FDG PET study,
posterior cingulate but not temporoparietal hypometabo-
lism predicted conversion to AD during 4–39 months of
follow-up (Minoshima et al, 1997). In 54 MCI patients
followed for 2 years, Tc-HMPAO SPECT showed decreased
left posterior cingulate blood flow in decliners compared to
nondecliners (Huang et al, 2002). Earlier FDG PET work in
AD patients suggested that neocortical abnormalities may
precede impairment of abstract reasoning and attention by
8–16 months (Grady et al, 1988).
In our recent report, we showed that the covariance
analytic method (SSM), but not traditional ROI analyses,
distinguished AD patients from control subjects (Scarmeas
et al, 2004). In ROI analyses in this longitudinal MCI study,
the posterior cingulate (flow reduction) was the only region
that predicted AD. However, it was not significant after
correcting for multiple comparisons, it was not significant
in Cox analyses, and its interaction with time was not
significant in most of the GEE analyses. These results
suggest that traditional ROI analyses were not as sensitive
as SSM, which was sensitive to cognitive decline for all
the neuropsychological measures examined in the GEE
PET network abnormalities and cognitive decline
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analyses. One caveat is that the atlas-based normalization
approach may not adequately capture hippocampal regions
because of spatial distortion, thus decreasing the sensitivity
of the ROI analysis for this region (Mosconi et al, 2005).
Further, it is not known if the SSM approach is superior to
other methods with potential utility in predicting cognitive
decline and conversion to AD in MCI patients, for example,
resting FDG PET (Silverman et al, 2002), hippocampal and
entorhinal atrophy on structural MRI (de Leon et al, 2004),
CSF tau and A-Beta levels (Blennow and Vanmechelen,
2003). Head-to-head comparison of these measures in larger
samples of MCI patients followed longitudinally is needed
to address this issue.
Cognitive activation paradigms using PET may improve
sensitivity, particularly in distinguishing AD from controls
(Stern et al, 2000; Grady et al, 2001; Horwitz et al, 1995).
However, in MCI patients, predictive utility for cognitive
activation paradigms is not established, and clinical
applicability is more limited than for resting PET.
There were several limitations to this study. H2
15O PET is
noisier and has lower resolution than FDG PET (Wu et al,
2003). The degree to which cerebral blood flow is coupled to
cerebral metabolism remains controversial (Mintun et al,
2001), and it is unclear if this coupling is maintained in MCI
and AD. In our MCI sample, the exclusion of subjects with
stroke and significant cerebrovascular disease suggests that
vascular pathology is an unlikely explanation for the
findings. Arterial blood was not sampled to provide
absolute quantification, partly due to practical limitations
and partly to make the PET procedure comparable to
general clinical usage. In several cases, MRI was not
conducted in temporal proximity to the PET scan, and
hence partial volume correction for atrophy could not be
done. The latter has a small but sometimes material effect in
the interpretation of PET data in distinguishing AD patients
from controls (Tanna et al, 1991; Meltzer et al, 1996). Our
sample size was small, thereby reducing statistical power.
However, the technique was powerful enough to demon-
strate significant effects on rates of change over time.
Another caveat is that the clinical diagnosis of AD is not
always accurate and could have led to error in diagnostic
outcome classification during follow-up. This issue was
partly addressed by the use of systematic diagnostic
methods and the evaluation of change over time in cognitive
performance (GEE analyses) that diminished the potential
bias in diagnostic assessment.
The damage that occurs in AD likely affects connections
in brain networks and is not restricted to the hippocampus
or entorhinal cortex. The covariance pattern that discrimi-
nated AD from controls also predicted cognitive decline
with forward application to an independent sample of MCI
patients, indicating that the expression of this AD pattern is
likely related to the disease process itself. Areas showing
decreased flow in the pattern included the cingulate,
inferior parietal lobule, and supramarginal gyrus, but the
parahippocampal region showed increased flow in this
pattern. As we previously suggested (Scarmeas et al, 2004),
it is possible that reduced flow because of AD pathology in
certain nodes of the pattern (cingulate, inferior parietal
lobule, and supramarginal gyrus) may affect the whole
pattern and lead to increased flow in another node in the
pattern (parahippocampal gyrus). This speculation is
supported by an MRI arterial spin labeling study showing
that hippocampal rCBF increased in very mild AD but then
gradually subsided as AD became more severe (Press et al,
2003), suggesting a possible compensatory hippocampal
response in very early AD.
Several regions in the AD covariance pattern, including
the posterior cingulate and inferior parietal lobule, are
known to be affected in AD. Posterior cingulate/flow deficits
have been shown in MCI and AD patients, even though this
region is not directly affected in very early AD (Huang et al,
2002; Braak and Braak, 1991). However, there are afferent
and efferent connections between the posterior cingulate
and the medial temporal cortex. The posterior cingulate
contributes to spatial orientation and spatial working
memory that may lie in parietal association area 7 and the
parahippocampal gyrus with spatially selective firing in
layer II of the entorhinal cortex (Huang et al, 2002).
Cortico-cortical disconnection between these regions may
lead to reduced metabolism in the posterior cingulate.
In summary, the covariance pattern previously shown to
discriminate AD from controls was shown to have
predictive utility for cognitive decline in an independent
sample of MCI patients. This independently validated
approach requires replication in large samples before
clinical application can be considered.
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